FDA Releases New Guidance on Real-World Drug Safety Studies
Published Date: 3/4/2026
Notice
Summary
The FDA just released new rules to help drug makers and researchers use real-world data to check medicine safety better and faster. This update affects anyone doing non-interventional studies on drugs, vaccines, or biologics, replacing older guidance and aiming to make safety checks smoother without extra costs. The new guidance is effective now and encourages clear planning, smart data use, and honest reporting to keep medicines safe for everyone.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Final M14 Guidance Available
The FDA issued the final ICH M14 guidance on March 4, 2026 for non-interventional studies that use real-world data to assess the safety of medicines (drugs, vaccines, and biological products). The guidance lays out recommended principles for planning, designing, analyzing, reporting, and submitting these studies.
Enhanced Methodology and Reporting Guidance
The final guidance includes comprehensive recommendations and enhanced discussion on Initial Design and Feasibility, the Conceptual Framework, quantitative bias analysis, and protocol development including characteristics and types of data sources. These revisions followed public comment and were incorporated before endorsement in September 2025.
Older Guidance Withdrawn and Draft Finalized
The final M14 guidance finalizes the July 5, 2024 draft and, upon publication, FDA intends to withdraw the prior guidance titled "Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data" published May 14, 2013. The final guideline was endorsed by ICH regulatory agencies in September 2025.
No New Paperwork Burden
The guidance contains no new collection of information under the Paperwork Reduction Act, and it references previously approved FDA information collections (for example, OMB control numbers 0910-0014, 0910-0001, and others).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-04252 — E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports; International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released new rules for drug companies on how to track and report safety info after a drug is approved. This update includes fresh ways to use data from places like social media and patient programs to keep medicines safe. Drug makers should get ready to follow these clearer, modern rules starting now, helping protect patients without extra costs.
Next: 2026-04255 — Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V SAPPHIRE
The Maritime Administration is checking if the foreign-built small passenger vessel M/V SAPPHIRE can be used for U.S. coastwise trade without hurting American shipbuilders or businesses. They want your thoughts by April 3, 2026, before making a decision. This affects companies using small passenger vessels and could impact the market for U.S.-built boats.